Business · 13/07/2020Updated: 10/17/2026 · 1 min read
InvaGen Pharmaceuticals, Inc. Withdraws Trandolapril Tablets ANDA Approval
Summary
The FDA is withdrawing approval of InvaGen's abbreviated new drug application for trandolapril tablets due to repeated failure to submit required data supporting bioequivalence, and the company waived its right to a hearing.